GLP-1 Medicines and Vision Changes: What People With Diabetes Should Know

Vision changes have many possible causes, and people with diabetes already have a higher risk of eye disease. Two separate topics come up with GLP-1 medicines: diabetic retinopathy getting worse when blood sugar improves quickly, and a rare optic-nerve condition called NAION that European regulators have linked to semaglutide. Neither means GLP-1 medicines routinely damage eyesight—but both are worth understanding.

What is diabetic retinopathy?

The US National Eye Institute describes diabetic retinopathy as diabetes-related damage to the blood vessels in the retina, the light-sensitive tissue at the back of the eye. It often causes no symptoms early on, which is why the NEI recommends a dilated eye exam at least once a year for people with diabetes.

Why rapid glucose improvement matters

The US labels for Mounjaro and Zepbound note that temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control. The Ozempic label reports that in a 2-year trial of people with type 2 diabetes at high cardiovascular risk, diabetic retinopathy complications occurred in 3.0% of people on semaglutide versus 1.8% on placebo. The increase was concentrated in people who already had retinopathy (8.2% vs 5.2%), compared with those who didn't (0.7% vs 0.4%).

The labels advise that people with a history of diabetic retinopathy be monitored for progression. So if you have retinopathy, eye care and diabetes care belong in the same conversation.

What about NAION?

Non-arteritic anterior ischemic optic neuropathy (NAION) happens when blood flow to the front of the optic nerve drops, and it can cause sudden vision loss, often in one eye.

In June 2025, the European Medicines Agency's safety committee concluded that NAION is a very rare side effect of semaglutide medicines (Ozempic, Rybelsus and Wegovy)—affecting up to 1 in 10,000 people taking them. The EMA said several large observational studies suggested that adults with type 2 diabetes taking semaglutide had about double the risk of NAION compared with non-users, which works out to roughly one extra case per 10,000 person-years of treatment. That's a relative doubling of a rare event, not a common risk.

Regulators don't always move in step. As of October 2026, the current US labels for Ozempic and Wegovy that we reviewed don't list NAION, so warnings can differ depending on where you live.

Which symptoms should not wait?

Sudden loss of vision, a curtain or shadow across your sight, new severe eye pain, a sudden shower of floaters, flashes of light, or rapidly worsening eyesight all need urgent assessment—the EMA advises contacting a doctor right away for sudden vision loss. Don't assume these are ordinary side effects. For milder changes, such as blurriness that comes and goes, contact your eye-care professional or clinician and mention which medicine you take and when the change started.

What to discuss before and during treatment

Tell your prescriber if you have diabetic retinopathy or other eye disease, and keep up with recommended eye exams. Ask whether improving glucose control should change your eye-check schedule. Please don't stop or change treatment because of a headline—but do treat sudden vision symptoms as a reason to get seen promptly.

Accurate wording matters here: there are specific signals and a rare risk, but no evidence supports a blanket claim that GLP-1 medicines cause blindness. For a broader look at diabetes outcomes, see what GLP-1 medicines can do for diabetes complications.